News & Events

Results of Operations and Financial Condition The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On May 7, 2026, Charles River Laboratories International, Inc. issued a press release providing financial re…

Regulation FD Disclosure The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Planned Divestiture of CDMO and Cell Solutions Businesses On February 25, 2026, Charles River Laboratories International, Inc. (t…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 18, 2026, the Company announced the appointment of Glenn Coleman as its Corporate Executive Vice President and Chief Financial Officer. Mr. Coleman will join the company with a tentative start date of April 6, 2026. Mr. Coleman, 58, will join Charles River with over 30 years of strong financial and operational management experience, inc…

Results of Operations and Financial Condition The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On February 18, 2026, Charles River Laboratories International, Inc. issued a press release providing financ…

Regulation FD Disclosure The Slide Presentation prepared in connection with the J.P. Morgan Conference also includes the following statements as to recent client demand trends and preliminary 2026 outlook: • Q4 DSA Trends: DSA demand trends continued to improve throughout the second half of 2025, resulting in preliminary DSA net book-to-bill of approximately 1.1x in the fourth quarter of 2025 – Improving trends during the second half of 2025 were primarily driven by small and mid-sized biotec…

above shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing. This Current Report on 8-K contains a forward-looking, non-GAAP financial measure: non-GAAP e…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Chief Executive Officer Transition On January 8, 2026, the Board of Directors (the “Board”) of Charles River Laboratories International, Inc. (the “Company”) announced a leadership transition plan. Mr. James C. Foster, our current Chairman of the Board, President and Chief Executive Officer, intends to step down as Chief Executive Officer and Chairm…

Regulation FD Disclosure The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Charles River Laboratories International, Inc. (“Charles River”, the “Company”, or the “Registrant”) is presenting at the Evercor…

Other Events As previously disclosed, on May 16, 2023, Charles River Laboratories International, Inc., (Company) received an inquiry from the Enforcement Division of the U.S. Securities and Exchange Commission (SEC) requesting it to voluntarily provide information, subsequently augmented with a document subpoena and additional inquiries, primarily related to the sourcing of non-human primates and related disclosures. In addition, the Company’s Audit Committee retained counsel to conduct an in…

to report the resignation of Flavia H. Pease as Corporate Executive Vice President, Chief Financial Officer of the Company and the appointment of Michael G. Knell as interim Chief Financial Officer of the Company. The Company is filing this Form 8-K/A to disclose details of Mr. Knell’s compensation that were not determined at the time of the original filing. On September 15, 2025, in connection with Mr. Knell’s appointment as interim Chief Financial Officer and interim principal financial off…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 20, 2025, Charles River Laboratories International, Inc. (the “Company”) and Mr. James C. Foster, Chair, President and Chief Executive Officer of the Company, entered into, and the Board approved, Amendment No. 1 (the “Foster Amendment”) to Mr. Foster’s Amended and Restated Employment Agreement with the Company, dated as of May 18, 2021 (the…

Other Events Purchase of Shares of Company Common Stock On February 20, 2025: • Mr. James C. Foster, Chair, President and Chief Executive Officer of Charles River Laboratories International, Inc. (the “Company”) purchased 6,075 shares of the Company’s common stock at an average price of $165.01 for an aggregate purchase price of approximately $1 million in open market transactions. • Ms. Birgit Girshick, Corporate Executive Vice President and Chief Operating Officer of the Company purchased 1…

Regulation FD Disclosure The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Charles River Laboratories International, Inc. ("Charles River", the "Company", or the “Registrant”) will be presenting at the 43…

Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective January 22, 2024, the Board of Directors (the "Board") of Charles River Laboratories International, Inc., (the "Company") increased the size of the Board from eleven to twelve. Following the size increase of the Board, the Board filled the vacancy and appointed Ms. Reshema Kemps-Polanco to the Board. Ms. Kemps-Polanco has been appointed t…

Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 9, 2023, Charles River Laboratories International, Inc. (the “Company”) announced that William D. Barbo, its Corporate Executive Vice President and Chief Commercial Officer, will retire from the Company at the end of 2024 after a distinguished, 42-year career with the Company. In the interim, Mr. Barbo will continue to serve as an Execut…

Other Events Purchase of Shares of Company Common Stock On November 14, 2023, Mr. James C. Foster, Chair, President and Chief Executive Officer of Charles River Laboratories International, Inc. (the “Company”) purchased 5,620 shares of the Company’s common stock at an average price of $178.05 for an aggregate purchase price of approximately $1.0 million in open market transactions. Mr. Foster indicated that he engaged in these transactions in recognition of the confidence he has in the strate…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective December 5, 2022, the Board of Directors (the "Board") of Charles River Laboratories International, Inc., (the "Registrant") increased the size of the Board from ten to eleven. Following the size increase of the Board, the Board filled the vacancy and appointed Dr. Craig B. Thompson to the Board. Dr. Thompson has been appointed to the Reg…

Regulation FD Disclosure. The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Charles River Laboratories International, Inc. (“Charles River”, the “Company”, or the “Registrant”) is virtually presenting at…

Regulation FD Disclosure. The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Charles River Laboratories International, Inc. ("Charles River", the "Company", or the “Registrant”) will be presenting at the W…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) As previously announced on January 11, 2022, David R. Smith intends to retire from Charles River Laboratories International, Inc. (the “Company”). Mr. Smith will step down from his position as Corporate Executive Vice President and Chief Financial Officer in connection with Flavia H. Pease’s appointment as the Company’s new Corporate Executive…

Regulation FD Disclosure. The following information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Charles River Laboratories International, Inc. (“Charles River” or the “Company”) will be presenting at the Credit Suisse 30 th…